High-Dose Calcitriol, Docetaxel and Zoledronic Acid in Patients with Castration-Resistant Prostate Cancer: A Phase II Study

Publisher： Karger

E-ISSN： 1423-0399|90|1|56-61

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.90, Iss.1, 2012-11, pp. : 56-61

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study

By  

Oncology, Vol. 90, Iss. 2, 2016-0 ,pp. : 69-78

Karger

Access to resources Recommend Favorite

Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer

By  

BJU INTERNATIONAL, Vol. 118, Iss. 4, 2016-10 ,pp. : 590-597

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of S-1 in Patients with Castration-Resistant Prostate Cancer: A Phase II Study

By  

Oncology, Vol. 78, Iss. 5-6, 2010-08 ,pp. : 323-328

Karger

Access to resources Recommend Favorite

High neutrophil‐to‐lymphocyte ratio predicts poor clinical outcome in patients with castration‐resistant prostate cancer treated with docetaxel chemotherapy

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 22, Iss. 9, 2015-09 ,pp. : 827-833

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study

By  

Oncology, Vol. 92, Iss. 2, 2016-12 ,pp. : 94-100

Karger

Access to resources Recommend Favorite